MNG32
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.476
- ANDROGEN_RESPONSE+0.271
- OXIDATIVE_PHOSPHORYLATION+0.251
- NOTCH_SIGNALING+0.229
- UV_RESPONSE_DN+0.225
- MYC_TARGETS_V1+0.171
- HEME_METABOLISM+0.116
- ADIPOGENESIS+0.105
- FATTY_ACID_METABOLISM+0.071
- SPERMATOGENESIS+0.029
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.436
- MYC_TARGETS_V2-0.386
- IL6_JAK_STAT3_SIGNALING-0.385
- E2F_TARGETS-0.383
- INFLAMMATORY_RESPONSE-0.369
- G2M_CHECKPOINT-0.364
- TNFA_SIGNALING_VIA_NFKB-0.364
- HEDGEHOG_SIGNALING-0.352
- INTERFERON_GAMMA_RESPONSE-0.339
- P53_PATHWAY-0.288
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1516042 | — | — | 0.837 |
| 2 | TCGA-50-5932-01A-11R-1755-07 | — | cohortA2 | 0.809 |
| 3 | SRR12202457 | — | — | 0.801 |
| 4 | MDT-AP-0180 | Med | Medulloblastoma | 0.795 |
| 5 | BS_Z7PKVY9J | Med | Medulloblastoma | 0.778 |
| 6 | MNG427 | — | — | 0.767 |
| 7 | TCGA-A7-A26E-01A-11R-A277-07 | — | D | 0.766 |
| 8 | 66290e22-72a1-4af2-93a6-e4859f91a7ef | — | — | 0.765 |
| 9 | DRR168589 | — | — | 0.764 |
| 10 | DRR168565 | — | — | 0.764 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.476 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.271 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.251 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.229 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.225 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.171 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.116 | Temsirolimus | — uncovered |
| ADIPOGENESIS | 0.105 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.071 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.029 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.029 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.025 | Cobimetinib | — uncovered |
| PEROXISOME | 0.020 | Idelalisib | — uncovered |